arrow
M

Mohamad Bassam Sonbol

Mayo Clinic
H指数:33
被引数:3,928

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The efficacy of standard-dose versus reduced-dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study

标准剂量与减量依维莫司在晚期神经内分泌肿瘤患者中的疗效比较:一项多中心回顾性队列研究

2026-10-070
PRE
Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

II期研究: futibatinib联合pembrolizumab治疗FGF19表达型晚期肝细胞癌患者的疗效观察

2026-08-250
OAAI
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer

TP53突变型晚期胆道癌的临床-分子特征及免疫检查点抑制剂疗效增强

2026-05-250
OAAI
Optimized dose schedule of rucaparib and liposomal irinotecan/5-fluorouracil in metastatic gastrointestinal cancers: A phase 1 study

rucaparib和脂质体伊立替康/5-氟尿嘧啶在转移性消化道肿瘤中的优化给药方案:一项1期研究

Cancer
IF5.1
2025-11-220
PRE
Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis

评估难治性转移性结直肠癌的三线疗法:一项系统评价和网络Meta分析

2025-10-280
PRE
Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis

Anjum MU,Naqvi SAA,Jajja SA,Raina A,Afzal MU,Faisal KS,等. 围手术期及新辅助疗法在胃癌和胃食管结合部腺癌中的疗效:一项网络Meta分析. Oncologist. (2025) 30:oyaf157. doi: 10.1093/oncolo/oyaf157.

2025-08-011
OA
Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC

使用数字病理学生物标志物QuantCRC改进错配修复精通II期结直肠癌的风险分层方案

2024-02-290
OA
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting
2024-01-014
PRE